Dual-targeting LILRB3/LILRB4 CAR-T cells for the treatment of monocytic acute myeloid leukemia.
New engineered immune cells targeting two proteins simultaneously show stronger activity against leukemic stem cells with minimal harm to healthy blood cells.
This preclinical study from Sichuan University's West China Hospital identifies LILRB3 and LILRB4 as co-expressed in monocytic AML including leukemic stem cells, then engineers a novel dual-targeting CAR-T that outperforms single-antigen approaches, particularly for double-positive tumor populations. The construct shows minimal off-target toxicity to normal HSPCs, addressing a key safety concern for AML CAR-T therapy, and establishes in vivo proof-of-concept across two xenograft models.
What the study was
- Study design
- preclinical_in_vitro_in_vivo
- Population
- Monocytic AML (FAB M4/M5)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochemical Pharmacology
Why it surfaced
Monocytic AML (FAB M4/M5) is a poor-prognosis AML subtype with no approved CAR-T; dual LILRB3/4 targeting is a novel mechanism not yet in clinical trials; State Key Laboratory imprimatur and multiple co-authors from Chinese Academy of Medical Sciences indicate strong institutional backing for translation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.